Serial Number 79395249
Registration 7602780
700

Registration Progress

Application Filed
Apr 3, 2024
Under Examination
Approved for Publication
Oct 29, 2024
Published for Opposition
Oct 29, 2024
Registered
Dec 17, 2024

Trademark Image

Basic Information

Serial Number
79395249
Registration Number
7602780
Filing Date
April 3, 2024
Registration Date
December 17, 2024
Published for Opposition
October 29, 2024
Drawing Code
2

Status Summary

Current Status
Active
Status Code
700
Status Date
Dec 17, 2024
Registration
Registered
Classes
005

Rights Holder

Boehringer Ingelheim International GmbH

99
Address
Binger Strasse 173
55218 Ingelheim
DE

Ownership History

Boehringer Ingelheim International GmbH

Original Applicant
99
DE

Boehringer Ingelheim International GmbH

Owner at Publication
99
DE

Boehringer Ingelheim International GmbH

Original Registrant
99
DE

Legal Representation

Attorney
Max Moskowitz

USPTO Deadlines

Next Deadline
1972 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-12-17)
Due Date
December 17, 2030
Grace Period Ends
June 17, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

23 events
Date Code Type Description Documents
Jun 27, 2025 FINV P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Jun 10, 2025 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Jun 9, 2025 FIMP P FINAL DISPOSITION PROCESSED Loading...
Mar 18, 2025 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Dec 17, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Dec 17, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Oct 29, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 29, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 9, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Sep 24, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 23, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 23, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 23, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 9, 2024 RFNT P REFUSAL PROCESSED BY IB Loading...
Aug 16, 2024 RFRR P REFUSAL PROCESSED BY MPU Loading...
Aug 16, 2024 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Aug 7, 2024 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Aug 6, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 30, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
May 21, 2024 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
May 21, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 20, 2024 LIMI I LIMITATION FROM ORIGINAL APPLICATION ENTERED Loading...
May 9, 2024 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the blood and blood forming organs; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections; pharmaceutical preparations for the prevention and treatment of oncological and auto-immune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of cancer, for treatment of immunological diseases, and treatment of infectious diseases.

Additional Information

Design Mark
The mark consists of an overall square-shaped design with round corners with the top left of the square curving around to the bottom left and to the top right appearing in blue and with a partial, incomplete circle appearing in purple comprising the bottom right of the design.
Color Claim
The color(s) blue and purple is/are claimed as a feature of the mark.

Classification

International Classes
005